<?xml version="1.0" encoding="UTF-8"?>
<p>Concerns that results from conventional trials can take years is proving false with hundreds of patients enrolled within 6 weeks in at least two SARS-CoV-2–specific clinical trials. Adaptive multicenter trials with interim analyses have the ability to determine if an intervention is superior to placebo and adjust the standard of care and move on to test new therapies in rapid succession. Once a new intervention has become standard of care, it can be tested against alternatives or combinations of drugs. For sites that don’t have the capacity to generate local trials, participation in platform trials like REMAP-CAP (The Randomised, Embedded, Multi-Factorial, Adaptive Platform Trial for Community-acquired Pneumonia) (
 <xref rid="bib14" ref-type="bibr">14</xref>) should be encouraged.
</p>
